{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:11:11Z","timestamp":1793797871769,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["B13026"],"award-info":[{"award-number":["B13026"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21975218"],"award-info":[{"award-number":["21975218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32101128"],"award-info":[{"award-number":["32101128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["51773176"],"award-info":[{"award-number":["51773176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jconrel.2023.01.052","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T19:09:47Z","timestamp":1675278587000},"page":"54-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Liver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells"],"prefix":"10.1016","volume":"355","author":[{"given":"Shenglong","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.01.052_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.730176","article-title":"Liver fibrosis: therapeutic targets and advances in drug therapy","volume":"9","author":"Tan","year":"2021","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0015","first-page":"1","article-title":"Combination therapy based on targeted nano drug co-delivery systems for liver fibrosis treatment: a review","author":"Zhou","year":"2022","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0020","first-page":"47","article-title":"Progress in drug delivery system for fibrosis therapy, Asian","volume":"16","author":"Xing","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0025","doi-asserted-by":"crossref","first-page":"304","DOI":"10.14218\/JCTH.2020.00023","article-title":"Antihepatic fibrosis drugs in clinical trials","volume":"8","author":"Guo","year":"2020","journal-title":"J Clin Transl Hepatol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","article-title":"Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases","volume":"16","author":"Hinz","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0035","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/jpet.118.256156","article-title":"Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis","volume":"370","author":"Chen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0040","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3390\/nano10101945","article-title":"Recent advances in nanomedicine for the diagnosis and therapy of liver fibrosis","volume":"10","author":"Bai","year":"2020","journal-title":"Nanomaterials."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0045","doi-asserted-by":"crossref","first-page":"231ra47","DOI":"10.1126\/scitranslmed.3008182","article-title":"Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance","volume":"6","author":"Hecker","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0050","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1124\/jpet.105.099499","article-title":"The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo","volume":"317","author":"Greupink","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"von Karstedt","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2023.01.052_bb0060","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.biopha.2018.12.004","article-title":"Insight into the role of TRAIL in liver diseases","volume":"110","author":"Jiang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0075","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.cellsig.2009.05.008","article-title":"Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells","volume":"21","author":"Park","year":"2009","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/jhep.2003.50002","article-title":"Activated stellate cells express the TRAIL receptor-2\/death receptor-5 and undergo TRAIL-mediated apoptosis","volume":"37","author":"Taimr","year":"2003","journal-title":"Hepatology."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fmats.2021.682844","article-title":"Long circulation of PEG-TRAIL improves anti-hepatic fibrosis effect of TRAIL via targeting activated hepatic stellate cells","volume":"8","author":"Lu","year":"2021","journal-title":"Front. Mater."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.28432","article-title":"Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells","volume":"64","author":"Oh","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/hep.28520","article-title":"Paving the TRAIL to anti-fibrotic therapy","volume":"64","author":"Guicciardi","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0100","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/14686996.2019.1590126","article-title":"Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review","volume":"20","author":"Shiraishi","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1248\/bpb.b13-00661","article-title":"Discussion about several potential drawbacks of PEGylated therapeutic proteins","volume":"37","author":"Zhang","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fphar.2020.00024","article-title":"Cell membrane-camouflaged nanocarriers for cancer diagnostic and therapeutic","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2019.10.032","article-title":"Recent advance of erythrocyte-mimicking nanovehicles: from bench to bedside","volume":"314","author":"Yang","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.052_bb0120","article-title":"PD-1 blockade cellular vesicles for cancer immunotherapy","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0125","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1021\/acsnano.8b04066","article-title":"Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics","volume":"12","author":"Li","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.052_bb0130","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1002\/adma.201602173","article-title":"Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors","volume":"28","author":"Sun","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0135","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jconrel.2020.01.054","article-title":"TRAIL-expressing cell membrane nanovesicles as an anti-inflammatory platform for rheumatoid arthritis therapy","volume":"320","author":"Shi","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.052_bb0140","doi-asserted-by":"crossref","first-page":"eabf7820","DOI":"10.1126\/sciadv.abf7820","article-title":"Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs","volume":"7","author":"Park","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0145","article-title":"Macrophage-evading and tumor-specific apoptosis inducing nanoparticles for targeted cancer therapy","author":"Liu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.01.052_bb0150","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0155","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1039\/D1BM01499D","article-title":"Resolving hepatic fibrosis via suppressing oxidative stress and an inflammatory response using a novel hyaluronic acid modified nanocomplex","volume":"9","author":"Ren","year":"2021","journal-title":"Biomater Sci."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0160","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41565-020-00836-6","article-title":"Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis","volume":"16","author":"Hu","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0165","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1038\/s41467-020-18042-2","article-title":"Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine","volume":"11","author":"Ferreira","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0170","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1021\/acsnano.8b06924","article-title":"Golgi apparatus-targeted chondroitin-modified Nanomicelles suppress hepatic stellate cell activation for the management of liver fibrosis","volume":"13","author":"Luo","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.052_bb0175","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbadis.2006.08.009","article-title":"Effects of retinoic acid on the development of liver fibrosis produced by carbon tetrachloride in mice","volume":"1772","author":"Wang","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2023.01.052_bb0180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41368-021-00144-2","article-title":"Fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage","volume":"13","author":"Sun","year":"2021","journal-title":"Int J Oral Sci."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0185","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","article-title":"Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120615","article-title":"Liver cirrhosis: An overview of experimental models in rodents","volume":"301","author":"Faccioli","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0195","article-title":"Red blood cell membrane-camouflaged PLGA nanoparticles loaded with basic fibroblast growth factor for attenuating Sepsis-induced cardiac injury","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0200","article-title":"Bioengineered multicellular liver microtissues for modeling advanced hepatic fibrosis driven through non-alcoholic fatty liver disease","volume":"17","author":"Cho","year":"2021","journal-title":"Small."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0210","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijpharm.2012.07.042","article-title":"A novel hybrid delivery system: polymer-oil nanostructured carrier for controlled delivery of highly lipophilic drug all-trans-retinoic acid (ATRA)","volume":"436","author":"Narvekar","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0215","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejpb.2014.04.014","article-title":"A new nanostructured carrier design including oil to enhance the pharmaceutical properties of retinoid therapy and its therapeutic effects on chemo-resistant ovarian cancer","volume":"88","author":"Narvekar","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0220","doi-asserted-by":"crossref","first-page":"2200856","DOI":"10.1002\/advs.202200856","article-title":"Autologous skin fibroblast-based PLGA nanoparticles for treating multiorgan fibrosis","volume":"9","author":"Long","year":"2022","journal-title":"Advanced Science."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0225","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/gutjnl-2019-318372","article-title":"Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells","volume":"69","author":"Mart\u00ed-Rodrigo","year":"2020","journal-title":"Gut."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0230","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/1061186X.2016.1262867","article-title":"Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells","volume":"25","author":"Arabpour","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0235","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2018.07.047","article-title":"New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment","volume":"286","author":"Jiang","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.052_bb0240","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.actbio.2014.10.002","article-title":"Hyaluronic acid-tumor necrosis factor-related apoptosis-inducing ligand conjugate for targeted treatment of liver fibrosis","volume":"12","author":"Yang","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0245","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41467-019-09101-4","article-title":"Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma","volume":"10","author":"Park","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0250","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","article-title":"Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0255","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/toxsci\/42.2.152","article-title":"Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins","volume":"42","author":"Bendele","year":"1998","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2020.01.036","article-title":"Cell membrane-camouflaged nanoparticles as drug carriers for cancer therapy","volume":"105","author":"Xu","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0265","article-title":"Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity","volume":"3","author":"Payen","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0270","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/cells10082129","article-title":"Heterogeneity of hepatic stellate cells in fibrogenesis of the liver: insights from single-cell transcriptomic analysis in liver injury","volume":"10","author":"Zhang","year":"2021","journal-title":"Cells."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0275","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-021-03549-5","article-title":"Cross-tissue organization of the fibroblast lineage","volume":"593","author":"Buechler","year":"2021","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell Mol Immunol."},{"key":"10.1016\/j.jconrel.2023.01.052_bb0285","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2013.12.025","article-title":"Macrophage heterogeneity in liver injury and fibrosis","volume":"60","author":"Tacke","year":"2014","journal-title":"J. Hepatol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:37:25Z","timestamp":1759163845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":57,"alternative-id":["S0168365923000615"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.052","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}